4.5 Article

Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder

Journal

EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 29, Issue 4, Pages 529-538

Publisher

ELSEVIER
DOI: 10.1016/j.euroneuro.2019.02.005

Keywords

Major depressive disorder; Treatment-resistant depression; Ketamine; Subjective experiences; Anxiety; Altered states of consciousness

Ask authors/readers for more resources

About 20 to 30 percent of patients with Major Depressive Disorder (MDD) do not respond to standard treatment and are considered treatment-resistant. The N-methyl-D-aspartate (NMDA) glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in treatment-resistant MDD, but it is unknown whether its acute psychological effects are related to the later antidepressant effect. Therefore, we investigated the association between antidepressant responses to ketamine and the quality of ketamine-induced psychological experiences in MDD. A total of 31 patients (M = 49.5 +/- 11.2 years, 16 women) were treated with three ketamine infusions per week (0.5 mg/kg over 40 min) administered for two consecutive weeks. Depression severity was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) at baseline, after four and 24 h and at end of treatment. The 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC) was applied four hours after the first infusion to assess the subjective quality of acute psychological effects. Patients with a >= 50% MADRS reduction from baseline to end of treatment were considered as responders. After six infusions, 17 of 31 patients (55%) showed a response to ketamine treatment, while 14 patients (45%) had no response. Anxiety-related experiences induced by ketamine were significantly higher in non-responders. Percentage MADRS reduction after four hours and individual levels of ketamine-induced anxiety were predictive of a response at end of treatment. The study demonstrated the considerable impact of ketamine-induced anxiety on the antidepressant efficacy of ketamine. It underpins the importance of considering patients' subjective experiences and underlines the possibility of a phenotypic response predictor. (C) 2019 Elsevier B.V. and ECNP. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available